BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35065392)

  • 1. Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.
    Haidopoulos D; Pergialiotis V; Aggelou K; Thomakos N; Alexakis N; Stamatakis E; Rodolakis A
    Surg Oncol; 2022 Mar; 40():101702. PubMed ID: 35065392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
    Jäger L; Nilsson PJ; Rådestad AF
    Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
    Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
    Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic exenteration for gynecologic malignancies: Postoperative complications and oncologic outcomes.
    Romeo A; Gonzalez MI; Jaunarena J; Zubieta ME; Favre G; Tejerizo JC
    Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):121-125. PubMed ID: 28911880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases.
    de Gregorio N; de Gregorio A; Ebner F; Friedl TWP; Huober J; Hefty R; Wittau M; Janni W; Widschwendter P
    Arch Gynecol Obstet; 2019 Jul; 300(1):161-168. PubMed ID: 31011878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of tumor size on outcomes following pelvic exenteration.
    Smith B; Jones EL; Kitano M; Gleisner AL; Lyell NJ; Cheng G; McCarter MD; Abdel-Misih S; Backes FJ
    Gynecol Oncol; 2017 Nov; 147(2):345-350. PubMed ID: 28822555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical results of pelvic exenteration in the treatment of gynecologic cancer.
    Petruzziello A; Kondo W; Hatschback SB; Guerreiro JA; Filho FP; Vendrame C; Luz M; Ribeiro R
    World J Surg Oncol; 2014 Sep; 12():279. PubMed ID: 25200866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Moolenaar LR; van Rangelrooij LE; van Poelgeest MIE; van Beurden M; van Driel WJ; van Lonkhuijzen LRCW; Mom CH; Zaal A
    Gynecol Oncol; 2023 Apr; 171():114-120. PubMed ID: 36870097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
    Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total pelvic exenteration for primary and recurrent malignancies.
    Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH
    World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?
    Egger EK; Liesenfeld H; Stope MB; Recker F; Döser A; Könsgen D; Marinova M; Hilbert T; Exner D; Ellinger J; Mustea A
    Anticancer Res; 2021 Jun; 41(6):3037-3043. PubMed ID: 34083295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.
    Jalloul RJ; Nick AM; Munsell MF; Westin SN; Ramirez PT; Frumovitz M; Soliman PT
    J Gynecol Oncol; 2018 Sep; 29(5):e68. PubMed ID: 30022632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature.
    Bizzarri N; Chiantera V; Ercoli A; Fagotti A; Tortorella L; Conte C; Cappuccio S; Di Donna MC; Gallotta V; Scambia G; Vizzielli G
    J Minim Invasive Gynecol; 2019; 26(7):1316-1326. PubMed ID: 30611973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival after pelvic exenteration for gynecologic malignancy.
    Westin SN; Rallapalli V; Fellman B; Urbauer DL; Pal N; Frumovitz MM; Ramondetta LM; Bodurka DC; Ramirez PT; Soliman PT
    Gynecol Oncol; 2014 Sep; 134(3):546-51. PubMed ID: 25014540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.
    Fotopoulou C; Neumann U; Kraetschell R; Schefold JC; Weidemann H; Lichtenegger W; Sehouli J
    J Surg Oncol; 2010 May; 101(6):507-12. PubMed ID: 20401918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies.
    Angeles MA; Mallet E; Rouanet P; Cabarrou B; Méeus P; Lambaudie E; Foucher F; Narducci F; Loaec C; Gouy S; Guyon F; Marchal F; Gladieff L; Martínez-Gómez C; Migliorelli F; Martinez A; Ferron G
    Int J Gynecol Cancer; 2020 Feb; 30(2):233-240. PubMed ID: 31796531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvic exenteration for primary and recurrent gynaecological malignancies.
    de Wilt JH; van Leeuwen DH; Logmans A; Verhoef C; Kirkels WJ; Vermaas M; Ansink AC
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):243-8. PubMed ID: 16950559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
    Matsuo K; Mandelbaum RS; Adams CL; Roman LD; Wright JD
    Gynecol Oncol; 2019 May; 153(2):368-375. PubMed ID: 30792003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
    Berek JS; Howe C; Lagasse LD; Hacker NF
    Gynecol Oncol; 2005 Oct; 99(1):153-9. PubMed ID: 16054678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
    Andikyan V; Khoury-Collado F; Sandadi S; Tew WP; O'Cearbhaill RE; Konner JA; Sonoda Y; Barakat RR; Chi DS; Abu-Rustum NR
    Int J Gynecol Cancer; 2013 Jun; 23(5):923-8. PubMed ID: 23698798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.